ATS View
한국어

NKGen Biotech Korea KRX:182400KOSDAQ

엔케이맥스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h2
Articles, 7 days8
DART filings, 7 days0
Articles tracked8since Sep 11

In Q2 2026, NKGen Biotech Korea reported revenue of ₩2.1bn, up 5.8% year on year, and an operating loss of ₩130m. NKGen Biotech Korea (엔케이맥스) appeared in 8 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 6 with 6 articles. The most common catalyst was tech & capacity (3). It was most often mentioned alongside JS Link and Seegene.

NKGen Biotech Korea quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩2.1bn+5.8%−₩130m
margin −6.1%		−₩191m
Q1 2026₩1.6bn+10.6%−₩1.2bn
margin −76.6%		−₩1.3bn
Q4 2025 derived₩2.2bn-0.8%−₩1.3bn
margin −61.0%		−₩783m
Q3 2025₩2.2bn-5.4%₩44m
margin 2.0%		₩216m
Q2 2025₩2.0bn-17.0%−₩905m
margin −44.8%		₩2.5bn
Q1 2025₩1.4bn-21.5%−₩527m
margin −37.0%		−₩77m
Q4 2024 derived₩2.2bn-9.5%₩4.6bn
margin 204.6%		₩6.1bn
Q3 2024₩2.3bn-13.1%−₩1.4bn
margin −59.4%		−₩9.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

NKGen Biotech Korea top stories 2 weeks, by number of outlets

  1. 1
    엔케이젠바이오텍코리아, '슬림바이365' 초도물량 20만 캡슐 완판
    5 outlets · 6 articlesFirst report Oct 6 10:37 뉴스핌New technology
  2. 2
    [빅데이터로본다] 생명과학서비스 상장기업 2026년 10월 브랜드평판... 1위 씨젠, 2위 제이에스링크, 3위 엔케이맥스
    2 outlets · 2 articlesFirst report Oct 7 04:25 일간투데이SeegeneJS Link

Latest NKGen Biotech Korea news Korean headlines